AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan…
News
XBiotech halts all rheumatology research after missing Phase II endpoints
GEMMABio raises $34m to advance gene therapy programmes
Novo gets the green light for once-daily haemophilia drug following setbacks
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment
FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea
SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines
